|
Reference
|
Year
|
Country
|
Design
|
Specimens No.
|
Patients No.
|
Age, yr
|
M/F
|
Test
|
Prior treatment
|
Occurrence
|
Gold Standard
|
Parameter
|
Cut-off
|
|---|
|
Meana
|
Median
|
|---|
|
Fueger et al. [12]
|
2010
|
US
|
17 Prospective+ 42 Retrospective
|
59
|
59 (22b)
|
–
|
44.5
|
13/9
|
PET or PET/CT
|
With (Sx + CT/RT) or without
|
New
|
Histo
|
SUVmax
|
2.72
|
|
Nioche et al. [32]
|
2013
|
France
|
Prospective
|
33
|
33
|
51 ± 16
|
51
|
28/5
|
PET/CT
|
With (Sx + CT/RT) or without
|
20 New+ 13 Recur
|
Histo
|
SUVmean
|
2.2
|
|
Pafundi et al. [24]
|
2013
|
US
|
Prospective
|
23
|
10 (9b)
|
42.9 ± 19.2
|
–
|
8/1
|
PET/CT
|
With or without
|
7 New+ 2 Recur
|
Histo
|
SUVmax T/SUVmean N
|
2.0
|
|
Janvier et al. [13]
|
2015
|
France
|
Retrospective
|
31
|
31
|
36.8 ± 12.1
|
–
|
13/18
|
PET
|
With (Sx/CT/RT) or without
|
25 New+ 6 Recur
|
Histo+Radio+follow-up
|
SUVmean T/N
|
1.33
|
|
Bund et al. [33]
|
2017
|
France
|
Prospective
|
53
|
53
|
38
|
–
|
23/30
|
PET/CT
|
Without
|
New
|
Histo
|
SUVmax T/N
|
2.16
|
|
Morana et al. [34]
|
2017
|
Italy
|
Retrospective
|
26
|
26
|
10.2 ± 4.6
|
9.5
|
15/11
|
PET
|
Without
|
New
|
Histo
|
SUVmax T/S
|
0.90
|
|
Patel et al. [35]
|
2018
|
US
|
Prospective
|
45
|
45
|
46.4 ± 16.2
|
–
|
22/23
|
PET
|
Without
|
New
|
Histo
|
SUVmax T/N
|
1.7
|
- M, male; F, female; Sx, surgery; CT, chemotherapy; RT, radiation therapy; New, newly-diagnosed; Recur, recurrent; Histo, histopathology; SUV, standardized uptake value; Radio, radiology; T, tumor; N, normal; S, Striatum
- aMean age is expressed as mean ± standard deviation
- bPatients that are finally included in the quantitative analysis by authors
